Alphamab Oncology Income Statement

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Operating Revenue	785.96	640.08	218.77	166.85	146.02	-
Revenue	785.96	640.08	218.77	166.85	146.02	-
Revenue Growth (YoY)	207.17%	192.58%	31.12%	14.26%	-	-
Cost of Revenue	60.77	60.32	55.24	44.21	3.03	-
Gross Profit	725.19	579.77	163.54	122.64	142.99	-
Selling, General & Admin	74.99	75.11	79.56	86.94	77.55	78.21
Research & Development	462.15	403.65	407.3	468.07	481.06	331.24
Operating Expenses	537.13	478.76	486.86	555.01	558.61	409.45
Operating Income	188.06	101.01	-323.33	-432.37	-415.62	-409.45
Interest Expense	-8.31	-9.92	-12.18	-14.21	-13.18	-11.83
Interest & Investment Income	38.7	49.26	74.04	33.87	27.81	64.66
Currency Exchange Gain (Loss)	4.5	13.45	33.19	66.71	-41.41	-122.15
Other Non Operating Income (Expenses)	9.85	12.56	17.68	20.28	29.99	51
EBT Excluding Unusual Items	232.81	166.34	-210.59	-325.72	-412.42	-427.77
Pretax Income	232.81	166.34	-210.59	-325.72	-412.42	-427.77
Earnings From Continuing Operations	232.81	166.34	-210.59	-325.72	-412.42	-427.77
Net Income	232.81	166.34	-210.59	-325.72	-412.42	-427.77
Net Income to Common	232.81	166.34	-210.59	-325.72	-412.42	-427.77
Shares Outstanding (Basic)	961	962	960	937	935	930
Shares Outstanding (Diluted)	995	984	960	937	935	930
Shares Change (YoY)	3.37%	2.53%	2.50%	0.11%	0.62%	73.29%
EPS (Basic)	0.24	0.17	-0.22	-0.35	-0.44	-0.46
EPS (Diluted)	0.24	0.17	-0.22	-0.35	-0.44	-0.46
Free Cash Flow	217.62	190.56	-239.02	-429.96	-478.72	-438
Free Cash Flow Per Share	0.22	0.19	-0.25	-0.46	-0.51	-0.47
Gross Margin	92.27%	90.58%	74.75%	73.50%	97.93%	-
Operating Margin	23.93%	15.78%	-147.79%	-259.14%	-284.63%	-
Profit Margin	29.62%	25.99%	-96.26%	-195.22%	-282.44%	-
Free Cash Flow Margin	27.69%	29.77%	-109.26%	-257.70%	-327.84%	-
EBITDA	251.82	165.36	-267.54	-391.83	-387.1	-390.47
EBITDA Margin	32.04%	25.83%	-122.29%	-234.85%	-265.10%	-
D&A For EBITDA	63.76	64.35	55.78	40.54	28.52	18.98
EBIT	188.06	101.01	-323.33	-432.37	-415.62	-409.45
EBIT Margin	23.93%	15.78%	-147.79%	-259.14%	-284.63%	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.